Adverum Biotechnologies initiates phase 3 ARTEMIS trial evaluating ixoberogene soroparvovec (Ixo-vec) in patients with wet AMD
Author(s): Martin David Harp Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered…